drugset / Trial / NCT06972992
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide
RandomizedSequentialTriple-blindTreatment
Summary
This will be a phase I, randomized, double-blind, placebo-controlled. This study will be conducted in three periods: the screening period, the treatment period, and the follow-up period.
Timeline
- Start
- 2025-04-18
- Primary completion
- 2025-09-22
- Completion
- 2025-09-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASC47 | Unknown | — | Subcutaneous |
| Background | Semaglutide | Peptide | — | — |
Indications
No indication recorded.